Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 19/20 | 0.63 |
| ▸ | PDE4D | Q08499 | 5/20 | 0.61 |
| ▸ | PDE4B | Q07343 | 4/20 | 0.61 |
| ▸ | PDE4C | Q08493 | 4/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6887553 | 0.99 | PDE4A (0.62) | PDE4APDE4DPDE4BPDE4C | |
| SCHEMBL8436326 | 0.97 | PDE4A (0.60) | PDE4APDE4DPDE4BPDE4C | |
| SCHEMBL6890101 | 0.95 | PDE4A (0.61) | PDE4APDE4DPDE4BPDE4C | |
| Hydrochloric Acid SCHEMBL6887550 | 0.93 | PDE4A (0.60) | PDE4APDE4DPDE4BPDE4C | |
| SCHEMBL7385364 | 0.88 | PDE4A (0.54) | PDE4APDE4DPDE4BPDE4C | |
| SCHEMBL6881979 | 0.84 | PDE4A (0.56) | PDE4APDE4DPDE4BPDE4C | |
| SCHEMBL7321228 | 0.84 | PDE4B (0.49) | PDE4APDE4DPDE4BPDE4C | |
| SCHEMBL1389001 | 0.83 | PDE4A (0.49) | PDE4APDE4DPDE4BPDE4C | |
| SCHEMBL7412691 | 0.83 | PDE4A (0.52) | PDE4APDE4DPDE4BPDE4C | |
| SCHEMBL7316969 | 0.83 | PDE4A (0.49) | PDE4APDE4DPDE4BPDE4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20010034450-A1 | Tetra-substituted phenyl derivatives and processes for their preparation | ALEXANDER RIKKI PETER (GB) | 2001-10-25 | — | — | US | claimed |
| EP-0640065-B1 | TRISUBSTITUTED PHENYL DERIVATIVES AS PHOSPHODIESTERASE INHIBITORS AND PROCESSES FOR THEIR PREPARATION | CELLTECH THERAPEUTICS LTD (GB) | 2001-10-17 | — | — | EP | claimed |
| EP-0766671-A1 | TETRA-SUBSTITUTED PHENYL DERIVATIVES USEFUL AS PDE IV INHIBITORS | CELLTECH THERAPEUTICS LIMITED (GB) | 1997-04-09 | — | — | EP | claimed |
| WO-1995035285-A1 | TETRA-SUBSTITUTED PHENYL DERIVATIVES USEFUL AS PDE IV INHIBITORS | CELLTECH THERAPEUTICS LIMITED (GB) | 1995-12-28 | — | — | WO | claimed |
| EP-2193808-A1 | Synergistic combination | Nycomed GmbH (DE) | 2010-06-09 | — | — | EP | disclosed |
| EP-0766671-B1 | TETRA-SUBSTITUTED PHENYL DERIVATIVES USEFUL AS PDE IV INHIBITORS | CELLTECH R&D LTD (GB) | 2004-09-29 | — | — | EP | disclosed |
| WO-2004047817-A1 | PDE4 AND PDE3/4 INHIBITORS FOR USE IN THE TREATMENT OF CACHEXIA | ALTANA PHARMA AG (DE) | 2004-06-10 | — | — | WO | disclosed |
| WO-2003024488-A2 | COMBINATION OF A PDE INHIBITOR AND A LEUKOTRIENE RECEPTOR ANTAGONIST | ALTANA PHARMA AG (DE) | 2003-03-27 | — | — | WO | disclosed |
| US-20010034450-A1 | Tetra-substituted phenyl derivatives and processes for their preparation | ALEXANDER RIKKI PETER (GB) | 2001-10-25 | — | — | US | disclosed |
| EP-0640065-B1 | TRISUBSTITUTED PHENYL DERIVATIVES AS PHOSPHODIESTERASE INHIBITORS AND PROCESSES FOR THEIR PREPARATION | CELLTECH THERAPEUTICS LTD (GB) | 2001-10-17 | — | — | EP | disclosed |
| US-6197792-B1 | PHOSPHODIESTERASE INHIBITOR | CELLTECH THERAPEUTICS LIMITED (GB) | 2001-03-06 | — | — | US | disclosed |
| US-5891896-A | Tri-substituted phenyl derivatives useful as PDE IV inhibitors | CELLTECH THERAPEUTICS LTD. (GB) | 1999-04-06 | — | — | US | disclosed |
| US-5859034-A | Tri-substituted phenyl compounds which have useful pharmaceutical activity | CELLTECH THERAPEUTICS, LIMITED (GB) | 1999-01-12 | — | — | US | disclosed |
| US-5849770-A | Tri-substituted phenyl derivatives useful as PDE IV inhibitors | CELLTECH THERAPEUTICS LTD. (GB) | 1998-12-15 | — | — | US | disclosed |
| US-5798373-A | Tri-substituted phenyl derivatives useful as PDE IV inhibitors | CELLTECH THERAPEUTICS, LIMITED (GB) | 1998-08-25 | — | — | US | disclosed |
| EP-0766671-A1 | TETRA-SUBSTITUTED PHENYL DERIVATIVES USEFUL AS PDE IV INHIBITORS | CELLTECH THERAPEUTICS LIMITED (GB) | 1997-04-09 | — | — | EP | disclosed |
| WO-1995035285-A1 | TETRA-SUBSTITUTED PHENYL DERIVATIVES USEFUL AS PDE IV INHIBITORS | CELLTECH THERAPEUTICS LIMITED (GB) | 1995-12-28 | — | — | WO | disclosed |
| EP-0640065-A1 | TRISUBSTITUTED PHENYL DERIVATIVES AS PHOSPHODIESTERASE INHIBITORS AND PROCESSES FOR THEIR PREPARATION | CELLTECH THERAPEUTICS LIMITED (GB) | 1995-03-01 | — | — | EP | disclosed |
| WO-1994020446-A1 | TRISUBSTITUTED PHENYL DERIVATIVES AS PHOSPHODIESTERASE INHIBITORS AND PROCESSES FOR THEIR PREPARATION | CELLTECH THERAPEUTICS LIMITED (GB) | 1994-09-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010034450-A1 | Tetra-substituted phenyl derivatives and processes for their preparation | CBR1, CSNK1A1L, NPY1R | PDE4A 4880/4885PDE4D 4883/4885PDE4B 4870/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.